Whitener Capital Management Inc. Sells 759 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Whitener Capital Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,777 shares of the biopharmaceutical company’s stock after selling 759 shares during the quarter. Whitener Capital Management Inc.’s holdings in Gilead Sciences were worth $736,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in GILD. Diversify Advisory Services LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter worth $316,000. Resonant Capital Advisors LLC lifted its stake in shares of Gilead Sciences by 12.6% during the 1st quarter. Resonant Capital Advisors LLC now owns 3,050 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 342 shares during the last quarter. Palisade Asset Management LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter worth $29,000. Choreo LLC lifted its stake in shares of Gilead Sciences by 22.3% during the 1st quarter. Choreo LLC now owns 9,963 shares of the biopharmaceutical company’s stock worth $730,000 after purchasing an additional 1,816 shares during the last quarter. Finally, Fidelis Capital Partners LLC raised its stake in Gilead Sciences by 20.8% in the first quarter. Fidelis Capital Partners LLC now owns 3,050 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 525 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 0.8 %

Gilead Sciences stock opened at $89.51 on Friday. The firm has a market cap of $111.44 billion, a price-to-earnings ratio of 109.16, a price-to-earnings-growth ratio of 3.09 and a beta of 0.17. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $89.74. The business’s 50-day moving average price is $83.79 and its 200 day moving average price is $74.16. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.61 by $0.40. The firm had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Analyst Ratings Changes

GILD has been the subject of a number of research analyst reports. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price target for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Barclays increased their price target on Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target for the company in a research note on Monday, July 8th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, October 9th. Finally, Truist Financial increased their price target on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Ten investment analysts have rated the stock with a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.85.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,847 shares of company stock valued at $3,033,340. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.